Mostrar el registro sencillo del ítem
Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma
dc.contributor.author | Trojan A. | |
dc.contributor.author | Lone Y.-C. | |
dc.contributor.author | Briceno I. | |
dc.contributor.author | Trojan J. | |
dc.date.accessioned | 2024-11-12T13:43:05Z | |
dc.date.available | 2024-11-12T13:43:05Z | |
dc.date.issued | 2024 | |
dc.identifier.issn | 9298673 | |
dc.identifier.other | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85185708388&doi=10.2174%2f0109298673237968231106095141&partnerID=40&md5=b4b108fc2f61f00d93fce204e96dce3a | |
dc.identifier.uri | http://hdl.handle.net/10818/62779 | |
dc.description.abstract | Objective: Vaccines for the deadliest brain tumor-glioblastoma (GBM)-are generally based on targeting growth factors or their receptors, often using antibodies. The vaccines described in the review were prepared to suppress the principal cancer growth factor-IGF-I, using anti-gene approaches either of antisense (AS) or of triple helix (TH) type. Our objective was to increase the median survival of patients treated with AS and TH cell vaccines. Methodology: The cells were transfected in vitro by both constructed IGF-I AS and IGF-I TH expression episomal vectors; part of these cells was co-cultured with plant phytochemicals, modulating IGF-I expression. Both AS and TH approaches completely suppressed IGF-I expression and induced MHC-1/B7 immunogenicity related to the IGF-I receptor signal. Results: This immunogenicity proved to be stronger in IGF-I TH than in IGF-I AS-prepared cell vaccines, especially in TH/phytochemical cells. The AS and TH vaccines generated an important TCD8+ and TCD8+CD11b-immune response in treated GBM patients and increased the median survival of patients up to 17-18 months, particularly using TH vaccines; in some cases, 2-and 3-year survival was reported. These clinical results were compared with those obtained in therapies targeting other growth factors. Conclusion: The anti-gene IGF-I vaccines continue to be applied in current GBM personalized medicine. Technical improvements in the preparation of AS and TH vaccines to increase MHC-1 and B7 immunogenicity have, in parallel, allowed to increase in the median survival of patients. © 2024 Bentham Science Publishers. | en |
dc.format | application/pdf | es_CO |
dc.language.iso | eng | es_CO |
dc.publisher | Current Medicinal Chemistry | es_CO |
dc.relation.ispartofseries | Current Medicinal Chemistry Vol. 31 N° 15 | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | Universidad de La Sabana | es_CO |
dc.source | Intellectum Repositorio Universidad de La Sabana | es_CO |
dc.subject.other | Anti-Gene Technology | en |
dc.subject.other | Cancer gene therapy | en |
dc.subject.other | Glioblastoma | en |
dc.subject.other | Igf-I | en |
dc.subject.other | Immuno-Gene Vaccine | en |
dc.subject.other | Signal transduction | en |
dc.title | Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma | en |
dc.type | journal article | es_CO |
dc.type.hasVersion | publishedVersion | es_CO |
dc.rights.accessRights | openAccess | es_CO |
dc.identifier.doi | 10.2174/0109298673237968231106095141 |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Facultad de Medicina [1345]